<DOC>
	<DOC>NCT03041116</DOC>
	<brief_summary>This study will investigate whether fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy, is safe and effective in treating patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN).</brief_summary>
	<brief_title>Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Patients</brief_title>
	<detailed_description />
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Pantothenate Kinase-Associated Neurodegeneration</mesh_term>
	<criteria>1. The patient has a diagnosis of PKAN as indicated by confirmed mutations in the pantothenate kinase 2 (PANK2) gene. 2. The patient is male or female aged 6 to 65 years, inclusive. 3. The patient has a score of &gt;6 on the PKANspecific activities of daily living measure (PKANADL) 1. The patient has required regular or intermittent invasive ventilatory support to maintain vital signs within 24 weeks prior to randomization. 2. The patient has had a deep brain stimulation (DBS) device implanted within 6 months prior to screening. 3. The patient has taken deferiprone within 30 days prior to screening. 4. The patient is unable to maintain stable doses of allowed concomitant medications for the first 24 weeks of the study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PKAN</keyword>
</DOC>